Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance.

Sandecká V, Hájek R, Pour L, Špička I, Ščudla V, Gregora E, Radocha J, Walterová L, Kessler P, Zahradová L, Adamová D, Valentova K, Vonke I, Obernauerová J, Starostka D, Wróbel M, Brožová L, Jarkovský J, Mikulášová A, Říhová L, Ševčíková S, Straub J, Minařík J, Adam Z, Krejčí M, Král Z, Maisnar V; Czech Myeloma Group.

Eur J Haematol. 2017 Jul;99(1):80-90. doi: 10.1111/ejh.12894. Epub 2017 May 11.

PMID:
28384387
2.

Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience.

Smetana J, Frohlich J, Zaoralova R, Vallova V, Greslikova H, Kupska R, Nemec P, Mikulasova A, Almasi M, Pour L, Adam Z, Sandecka V, Zahradová L, Hajek R, Kuglik P.

Biomed Res Int. 2014;2014:209670. doi: 10.1155/2014/209670. Epub 2014 Jun 2.

3.

Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse.

Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, Sandecka V, Adam Z, Krejci M, Kuglik P, Hajek R.

Haematologica. 2014 Feb;99(2):360-4. doi: 10.3324/haematol.2013.094409. Epub 2013 Sep 13.

4.

Efficient use of basic biochemical methods to prove the presence of monoclonal protein in the clinical diagnosis of malignant monoclonal gammopathy.

Cermáková Z, Gottwaldová J, Dastych M, Adam Z, Zahradová L.

Clin Chem Lab Med. 2013 Oct;51(10):e243-5. doi: 10.1515/cclm-2013-0090. No abstract available.

PMID:
23633467
5.

[Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].

Adam Z, Stork M, Pour L, Krejčí M, Zahradová L, Sandecká V, Hájek R, Cermáková Z, Pospíšilová Y, Navrátil M, Král Z, Mayer J.

Vnitr Lek. 2012 Dec;58(12):896-903. Czech.

PMID:
23427947
6.

Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.

Smetana J, Berankova K, Zaoralova R, Nemec P, Greslikova H, Kupska R, Mikulasova A, Frohlich J, Sevcikova S, Zahradova L, Krejci M, Sandecka V, Almasi M, Kaisarova P, Melicharova H, Adam Z, Penka M, Jarkovsky J, Jurczyszyn A, Hajek R, Kuglik P.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):123-30. doi: 10.1016/j.clml.2012.11.012. Epub 2013 Jan 4.

PMID:
23291040
7.

[The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis].

Adam Z, Pour L, Krejčí M, Zahradová L, Szturz P, Koukalová R, Rehák Z, Nebeský T, Hájek R, Král Z, Mayer J.

Vnitr Lek. 2012 Nov;58(11):856-66. Review. Czech.

PMID:
23256832
8.

Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.

Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R.

PLoS One. 2012;7(10):e47077. doi: 10.1371/journal.pone.0047077. Epub 2012 Oct 10.

9.

[Cladribine is highly effective in the treatment of Langerhans cell histiocytosis and rare histiocytic disorders of the juvenile xanthogranuloma group].

Adam Z, Szturz P, Pour L, Krejčí M, Zahradová L, Tomíška M, Král Z, Koukalová R, Rehák Z, Mayer J.

Vnitr Lek. 2012 Jun;58(6):455-65. Review. Czech.

PMID:
22913238
10.

[Eyelids with yellow granulomas and cough - periocular xanthogranuloma associated with adult-onset asthma. A case study and an overview of clinical forms of juvenile xanthogranuloma and its therapy].

Adam Z, Veselý K, Motyčková I, Szturz P, Koukalová R, Rehák Z, Stouracová A, Vaníček J, Krejčí M, Pour L, Zahradová L, Hájek R, Král Z, Mayer J.

Vnitr Lek. 2012 May;58(5):365-77. Review. Czech.

PMID:
22716172
11.

[Interleukin-1 receptor blockade with anakinra provided cessation of fatigue, reduction in inflammation markers and regression of retroperitoneal fibrosis in a patient with Erdheim-Chester disease - case study and a review of literature].

Adam Z, Szturz P, Bučková P, Cervinková I, Koukalová R, Rehák Z, Krejčí M, Pour L, Zahradová L, Hájek R, Král Z, Mayer J.

Vnitr Lek. 2012 Apr;58(4):313-8. Review. Czech.

PMID:
22559807
12.

Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results.

Zahradova L, Mollova K, Ocadlikova D, Kovarova L, Adam Z, Krejci M, Pour L, Krivanova A, Sandecka V, Hajek R.

Neoplasma. 2012;59(4):440-9. doi: 10.4149/neo_2012_057.

PMID:
22489700
13.

[The role of PET-CT in decision making on the treatment of localized nodular form of pulmonary AL-amyloidosis].

Adam Z, Elleder M, Moulis M, Tichý M, Cervinková I, Rehák Z, Koukalová R, Fojtík Z, Hanke I, Pour L, Krejčí M, Zahradová L, Szturz P, Hájek R, Král Z, Mayer J.

Vnitr Lek. 2012 Mar;58(3):241-52. Czech.

PMID:
22486293
14.

[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation].

Adam Z, Rehák Z, Koukalová R, Szturz P, Krejčí M, Pour L, Zahradová L, Moulis M, Kodet R, Nebeský T, Brejcha M, Adamová Z, Hájek R, Mayer J.

Vnitr Lek. 2012 Jan;58(1):62-71. Czech.

PMID:
22448704
15.

[Six-year follow-up of a patient with multiple angiomatosis involving skeleton, thoracic and abdominal cavities and the gut wall].

Adam Z, Matýšková M, Tomíška M, Rehák Z, Koukalová R, Křikavová L, Pour L, Krejčí M, Szturz P, Zahradová L, Mechl M, Moulis M, Vaníček J, Neuman C, Navrátil M, Veselý K, Hájek R, Mayer J.

Klin Onkol. 2012;25(1):47-62. Czech.

PMID:
22348220
16.

Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma.

Szturz P, Řehák Z, Koukalová R, Adam Z, Krejčí M, Pour L, Zahradová L, Vaníček J, Nebeský T, Hájek R, Mayer J.

Nucl Med Biol. 2012 Apr;39(3):429-36. doi: 10.1016/j.nucmedbio.2011.10.002. Epub 2011 Dec 14.

PMID:
22172385
17.

[MR-documented remission of pituitary stalk infiltration in patients with Langerhans cell histiocytosis following treatment with 2-chlorodeoxyadenosine].

Vanícek J, Adam Z, Balsíková K, Krejcí M, Pour L, Szturz P, Zahradová L, Hájek R, Koukalová R, Rehák Z, Král Z, Mayer J.

Vnitr Lek. 2011 Oct;57(10):871-5. Czech.

PMID:
22097697
18.

[Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide].

Adam Z, Sprláková A, Rehák Z, Koukalová R, Szturz P, Krejcí M, Pour L, Zahradová L, Cervinek L, Kren L, Moulis M, Hermanová M, Mechl M, Prásek J, Hájek R, Král Z, Mayer J.

Klin Onkol. 2011;24(5):367-81. Czech.

PMID:
22070019
19.

Lenalidomide: a new treatment option for Castleman disease.

Szturz P, Adam Z, Chovancová J, Stehlíková O, Klabusay M, Rehák Z, Koukalová R, Krejčí M, Pour L, Zahradová L, Hájek R, Mayer J.

Leuk Lymphoma. 2012 Oct;53(10):2089-91. doi: 10.3109/10428194.2011.621564. Epub 2011 Dec 5. No abstract available.

PMID:
21902577
20.

Prognostic significance of morphological assessment of plasma cells in multiple myeloma.

Al-Sahmani M, Trnavska I, Sevcikova S, Antosova M, Antosova L, Kissova J, Adam Z, Pour L, Nemec P, Greslikova H, Krejci M, Zahradova L, Bulikova A, Penka M, Hajek R.

Neoplasma. 2011;58(6):554-60.

PMID:
21895410
21.

Multiple myeloma associated IgA pemphigus: treatment with bortezomib- and lenalidomide-based regimen.

Szturz P, Adam Z, Klincová M, Feit J, Krejčí M, Pour L, Zahradová L, Vašků V, Hájek R, Mayer J.

Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):517-20. doi: 10.1016/j.clml.2011.06.014. No abstract available.

PMID:
21856265
22.

[Successful treatment of Erdheim-Chester disease by 2-chlorodeoxyadenosine-based chemotherapy. Two case studies and a literature review].

Adam Z, Koukalová R, Sprláková A, Rehák Z, Cervinek L, Szturz P, Krejcí M, Pour L, Zahradová L, Moulis M, Prásek J, Chaloupka R, Hájek R, Mayer J.

Vnitr Lek. 2011 Jun;57(6):576-89. Review. Czech.

PMID:
21751544
23.

[Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen].

Szturz P, Jakubcová R, Adam Z, Klincová M, Krejcí M, Pour L, Zahradová L, Hájek R, Mayer J.

Klin Onkol. 2011;24(3):216-20. Czech.

PMID:
21717791
24.

[Kidney failure in a patient with chronic B-lymphocytic leukaemia (B-CLL) with underlying cast nephropathy. The value of free immunoglobulin light chain identification for early diagnosis of this complication].

Adam Z, Stepánková S, Sirotková A, Cermáková Z, Pour L, Krejcí M, Zahradová L, Korístek Z, Lenz J, Hájek R, Vorlícek J, Mayer J.

Vnitr Lek. 2011 Feb;57(2):214-21. Czech.

PMID:
21416862
25.

Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.

Krejci M, Gregora E, Straub J, Minarik J, Scudla V, Adam Z, Krivanova A, Pour L, Zahradova L, Buchler T, Mayer J, Hajek R.

Ann Hematol. 2011 Dec;90(12):1441-7. doi: 10.1007/s00277-011-1206-3. Epub 2011 Mar 5.

PMID:
21380511
26.

[Diffuse plane normolipemic xanthomatosis and necrobiotic xanthogranuloma associated with monoclonal gammopathy--determining the disease stage with PET-CT and treatment experience. Two case studies and literature review].

Adam Z, Zahradová L, Krejcí M, Pour L, Koukalová R, Rehák Z, Feit J, Kren L, Mechl M, Vasků V, Sirotková A, Hájek R, Mayer J.

Vnitr Lek. 2010 Nov;56(11):1158-68. Review. Czech.

PMID:
21250495
27.

[Successful treatment of angiomatosis with thalidomide and interferon alpha. A description of five cases and overview of treatment of angiomatosis and proliferating hemangiomas].

Adam Z, Pour L, Krejcí M, Pourová E, Synek O, Zahradová L, Navrátil M, Mechl M, Nebeský T, Neubauer J, Feit J, Vokurková J, Král Z, Bednarík O, Slampa P, Dolezalová H, Hájek R, Mayer J.

Vnitr Lek. 2010 Aug;56(8):810-23. Review. Czech.

PMID:
20845613
28.

[Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].

Adam Z, Pour L, Krejcí M, Zahradová L, Krivanová A, Mardová J, Kovárová L, Stepánková S, Moulis M, Kren L, Veselý K, Svobodová I, Germáková Z, Nedbálková M, Mayer J, Hájek R.

Vnitr Lek. 2010 Mar;56(3):190-209. Review. Czech.

PMID:
20394205
29.

Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.

Greslikova H, Zaoralova R, Filkova H, Nemec P, Oltova A, Kupska R, Rudolecka P, Smetana J, Pour L, Zahradova L, Krejci M, Buchler T, Adam Z, Hajek R, Kuglik P.

Neoplasma. 2010;57(2):111-7.

PMID:
20099973
30.

Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.

Nemec P, Zemanova Z, Greslikova H, Michalova K, Filkova H, Tajtlova J, Kralova D, Kupska R, Smetana J, Krejci M, Pour L, Zahradova L, Sandecka V, Adam Z, Buchler T, Spicka I, Gregora E, Kuglik P, Hajek R.

Biol Blood Marrow Transplant. 2010 Apr;16(4):548-54. doi: 10.1016/j.bbmt.2009.11.025. Epub 2010 Jan 18.

31.

Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.

Krejci M, Scudla V, Tothova E, Schutzova M, Koza V, Adam Z, Krivanova A, Pour L, Buchler T, Sandecka V, Kralova D, Zahradova L, Vorlicek J, Mayer J, Hajek R.

Clin Lymphoma Myeloma. 2009 Dec;9(6):436-42. doi: 10.3816/CLM.2009.n.086.

PMID:
19951883
32.

Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma.

Krejci M, Adam Z, Buchler T, Krivanova A, Pour L, Zahradova L, Holanek M, Sandecka V, Mayer J, Vorlicek J, Hajek R.

Ann Hematol. 2010 May;89(5):483-7. doi: 10.1007/s00277-009-0862-z. Epub 2009 Nov 19.

PMID:
19924414
33.

Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance.

Kovarova L, Buresova I, Buchler T, Suska R, Pour L, Zahradova L, Penka M, Hajek R.

Neoplasma. 2009;56(6):526-32.

PMID:
19728762
34.

[The preparation of anticancer vaccine for patients with multiple myeloma on the base of monoclonal immunoglobulin loaded dendritic cells].

Ocadlíková D, Zahradová L, Kovárová L, Smejkalová J, Pour L, Vidláková P, Kyjovská D, Moravcová J, Rycová M, Novotná H, Jelínková I, Penka M, Michálek J, Hájek R.

Klin Onkol. 2009;22(2):67-72. Czech.

PMID:
19522376
35.

Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.

Pour L, Adam Z, Buresova L, Krejci M, Krivanova A, Sandecka V, Zahradova L, Buchler T, Vorlicek J, Hajek R.

Clin Lymphoma Myeloma. 2009 Apr;9(2):151-3. doi: 10.3816/CLM.2009.n.036.

PMID:
19406726
36.

[Treatment of Waldenström macroglobulinaemia--the experience of one centre].

Adam Z, Pour L, Krejcí M, Korístek Z, Navrátil M, Krivanová A, Zahradová L, Hájek R.

Vnitr Lek. 2009 Jan;55(1):9-17. Czech.

PMID:
19227950
37.

Dendritic cell counts and their subsets during treatment of multiple myeloma.

Kovarova L, Buchler T, Pour L, Zahradova L, Ocadlikova D, Svobodnik A, Penka M, Vorlicek J, Hajek R.

Neoplasma. 2007;54(4):297-303.

PMID:
17822319
38.

Isolation and expansion of allogeneic myeloma-specific interferon-gamma producing T cells for adoptive immunotherapy.

Ocadlikova D, Zahradova L, Kovarova L, Penka M, Zaloudik J, Buchler T, Hajek R, Michalek J.

Med Oncol. 2006;23(3):377-84.

PMID:
17018895

Supplemental Content

Loading ...
Support Center